Q-omics provides the consensus-scored SPART profile across patient tissues and cancer cell-line models. SPART expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SPART is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, SPART RNA expression shows 20,643 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, COAD, and UVM as cancer lineages where SPART shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPART — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPART survival associations across molecular data types. SPART RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPART RNA expression–survival associations across cancer types. High SPART expression shows unfavorable associations in UVM and BLCA, but favorable associations in KIRC, UCS, MESO and PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SPART RNA expression.
This table summarizes SPART tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 8. The strongest signals are observed in LUAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for SPART. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPART shows lower tumor expression in COAD, LUAD, THCA, KICH, LUSC and BLCA. The COAD box plot shows higher SPART RNA expression in normal versus tumor tissue (log2 FC = −1.233, t-test p < 0.001).
This table shows molecular features associated with SPART in patient tissues and cancer cell lines. In patient samples, SPART shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, SPART RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
